Quick Summary
- PE acquisitions of med spas follow a predictable, stage-by-stage process — and that process is designed to favor the buyer at every stage unless the seller knows exactly what’s happening and when.
- The difference between a represented and unrepresented seller is 1.5–2x EBITDA. On a $1M EBITDA practice, that’s $1.5M–$2M gone. Permanently. With no recourse after the wire clears.
- The first offer you received is not a fair offer. It is a floor. And the competitive process is the only mechanism that forces a PE buyer to show you the ceiling.
Table of Contents[Hide][Show]
If you’ve received an unsolicited offer from a private equity firm, read this before you say another word to that buyer.
Not because the offer is necessarily dishonest. Not because the people who sent it aren’t genuine. But because you are about to enter a process their deal team has run dozens of times — and you haven’t run it once. Every stage of a PE acquisition is structured. Every question they ask has a purpose. And most of what happens between “first conversation” and “wire transfer” is invisible to an unrepresented seller until it’s too late to change the outcome.
The gap between knowing this process and learning it after the fact is real money. On a $1M EBITDA practice, unrepresented sellers leave $1.5M–$2M on the table on average. That’s not a negotiation gap. That’s a permanent, irreversible loss with no recourse after the wire clears.
Here’s what actually happens at every stage.
Why Private Equity Is Buying Med Spas Right Now
The consolidation math
PE firms acquire individual practices at standalone multiples, combine them into regional platforms, and exit the platform at institutional multiples. The math is direct: deploy $47M across a series of add-on acquisitions, build a platform with centralized infrastructure and recurring EBITDA, and exit at $83M. That’s the buy-and-build playbook — and it works precisely because individual practices transact at lower multiples than consolidated platforms.
Your practice, at $1M–$3M EBITDA, might transact at 5x–9x as a standalone. Inside a mature platform, that same EBITDA is worth 10x–14x. PE firms are capturing the multiple expansion. The question is how much of it you capture too.
The window is open — but not permanently
According to the American Med Spa Association’s 2024 State of the Industry Report, only 3%–4% of medspas are currently PE-consolidated. There are 30+ active PE platforms competing right now for quality independent practices. That gap is what gives well-represented sellers genuine leverage — but it won’t hold at 3%–4% indefinitely.
The 2025 market saw the first year-over-year revenue declines in the aesthetic space, driven by oversaturated supply meeting softer demand. PE buyers are conducting significantly more rigorous diligence than they did in 2020–2022. The window is real. It is also narrowing — not this quarter, but over the next 3–5 years, the leverage profile shifts decisively toward buyers.
What EBITDA Multiples Are Med Spas Actually Getting?
Single-location vs. multi-location
The multiple range in this market is wide enough that two practices with identical gross revenue can produce dramatically different outcomes at closing.
Single-location med spas currently transact at 4x–9x adjusted EBITDA. Multi-location platforms — two or three locations — reach 7x–13x+. Each additional profitable, well-run location adds roughly 0.5x–1.0x to the multiple. The jump from single to even a two-location footprint is the highest-ROI structural move available before an exit.
That said, multi-location only helps if the additional locations are profitable and clean. Expanding into underperforming units — a mistake we see constantly — destroys the margin story that justifies a premium multiple. “I thought going bigger, I’d make more and work less. It’s been the exact opposite.”
What compresses your multiple
Four variables compress a multiple faster than anything else:
Owner concentration. If you’re personally performing 60% or more of treatments, buyers price the risk that your departure equals patient attrition. Practices in that position transact at 3.5x–5.0x. Practices where the owner has shifted into a management-only role transact at 7.0x–9.0x and above. That’s millions of dollars inside a staffing decision you can control — but not in the 90 days before a sale.
Device debt. High-APR financing on lasers and body contouring equipment compresses your EBITDA directly. Buyers read through the revenue line; they’re buying margin, not machines.
No documented SOPs. A practice that cannot operate for 30 days without the owner is not a transferable business. It’s a job. PE buyers are acquiring systems, not personal goodwill.
Revenue mix. Membership-based, recurring revenue commands higher multiples than one-time treatment revenue. Buyers pay for predictability.
How the PE Acquisition Process Actually Works — Stage by Stage
First contact and the NDA
Most PE acquisitions of med spas begin with a cold outreach — a call, an email, an introduction through an industry contact. It feels conversational. It isn’t.
By the time a PE firm reaches out directly, they’ve already identified you as a target, mapped your market footprint, and estimated your EBITDA from publicly available signals. The “getting to know you” call is a data-gathering exercise. Everything you say about revenue, margins, staff structure, or ownership timeline is used to construct their opening offer — and a lower one, if the information supports it.
Do not have a substantive conversation with an inbound PE buyer before representation is in place. Not because they’re dishonest — because they are institutionally trained for this conversation and you are not.
The NDA arrives early. Sign it — but read it. NDAs in this context sometimes include standstill provisions that can limit your ability to approach other buyers while the initial relationship develops. Your advisor reviews this before it’s in front of you.
The CIM and marketing process
If you’re working with a sell-side advisor, the process looks different from the start. Your advisor prepares a Confidential Information Memorandum (CIM) — a structured presentation of your practice’s financials, growth story, market position, and operational profile. This document goes to multiple qualified buyers simultaneously.
This is how a competitive process begins. Not one friendly conversation — multiple parallel conversations, with buyers who know they’re not the only name in the room.
CIM quality matters. Buyers read dozens of these. A professionally prepared CIM signals that the seller is organized, represented, and not desperate — and it pre-answers the diligence questions that buyers otherwise use to justify lower offers.
LOI, exclusivity, and the most dangerous moment
The Letter of Intent is where most sellers exhale. Don’t.
An LOI is not a closed deal. It is an agreement to negotiate exclusively — and that exclusivity window, typically 45–90 days, is the most structurally dangerous period in the entire process.
Here’s what happens inside exclusivity: the PE firm’s diligence team goes to work. They surface issues — compliance gaps, owner concentration risk, lease terms, payroll classification inconsistencies. In a competitive process, those issues are negotiated. In an uncontested exclusivity period, they become the justification for a price reduction. This is the re-trade.
Re-trading is not a surprise tactic. It’s a documented, institutional practice. The buyer locks in exclusivity, invests 60 days of diligence resources, and returns with a revised offer. The seller — exhausted, committed, and without competitive alternatives — accepts a number below the LOI. The proceeds you mentally allocated evaporate.
What’s negotiable in an LOI that most sellers don’t know to negotiate: the exclusivity window length, the material adverse change definition, reps and warranties scope, and — critically — the earn-out structure and rollover percentage. An experienced advisor negotiates these before the LOI is signed. Almost impossible to revisit after.
Due diligence — the QoE, the re-trade, and how to survive it
The Quality of Earnings (QoE) is the diligence document that can crater a deal. PE firms commission an independent QoE from their accounting firm — not yours — to validate the EBITDA you’ve represented. Add-backs get challenged. One-time revenue items are stripped out. Compliance issues surface.
In one documented case, a compliance discovery dropped the per-unit deal value from $100 to $62 — a 38% reduction after LOI exclusivity had already begun.
The preparation you do before diligence determines how much of the LOI price survives to closing. Clean financials, documented SOPs, properly categorized expenses, and pre-prepared add-back schedules are the difference between a diligence process that confirms value and one that erodes it. This work takes 12–18 months to do right. It cannot be compressed into the 30 days before you respond to an inbound inquiry.
Close, the wire, and what rollover equity actually means
Closing day feels like the finish line. The wire is real. But the full deal structure almost always includes more than cash at close.
Most PE acquisitions include an equity rollover — the seller retains a percentage of equity in the new platform rather than taking 100% cash. The pitch is the “second bite of the apple”: when the PE firm exits the platform 3–7 years later, your rolled equity participates at platform multiples. The math is real — $47M in, $83M out means that second bite can be substantial.
But hear this clearly: value the rollover at zero in your decision. Not because it won’t pay out. Because if the deal only makes sense with the rollover included, it isn’t the right deal. Your guaranteed cash at close is the only number you can bank on day one.
The same logic applies to earn-outs. Deferred payments tied to post-close EBITDA metrics are controlled by a buyer who now controls operations. They routinely fail to materialize — for documented reasons in documented cases. Treat earn-outs as zero in your analysis. Structure the deal so the cash at close is the deal.
Where Sellers Lose Money (And Don’t Know It Until It’s Too Late)
The unrepresented seller discount
60%+ of med spa owners engage PE buyers without representation — often inadvertently, by responding to a “friendly” first call before realizing the negotiation has started. Sellers who engage experienced M&A advisors achieve 23% higher EBITDA multiples on average (HealthFMV benchmarking). On a $1M EBITDA practice at a 7x multiple, that’s $1.6M — before the compounding effect of improved deal terms.
In one documented case, a founder nearly accepted a $45M unsolicited offer. A properly run competitive process produced $125M. $80M left on the table. Permanently.
The re-trade playbook
It works because it’s engineered to work. The buyer builds a relationship, creates a sense of momentum and mutual investment, and closes exclusivity before a second offer enters the room. Once exclusivity is signed, the seller has no competitive alternative. The price reduction lands when they’re most exhausted and most committed.
The friendly buyer is often the most dangerous counterpart.
The earn-out trap
Value the rollover at zero. Value earn-outs at zero. Not pessimism — math. Guaranteed cash at close is the deal. Every other number is a projection controlled by someone else.
Before you respond to any offer — even a “just getting to know you” call — this is the conversation to have first. A 30-minute call with Bill Walker. No obligation. No pitch. Just a straight read on where you stand. [Schedule a Call →]
PE Affiliation vs. DSO Workback — The Distinction That Changes Everything
Not all PE deals are the same structure. The most important distinction is between a PE affiliation and a DSO workback — and most sellers don’t know to ask which they’re being offered.
In a well-structured PE affiliation, you sell the management company, retain clinical autonomy, continue building patient and team relationships, and participate in the platform’s upside through rolled equity. The commitment period — how long you’re contractually obligated to remain active post-close — is negotiable. We’ve reduced commitment windows from 5 years to 2 years in documented transactions, with maintained autonomy provisions and $2M more at closing than the original unsolicited offer.
In a DSO workback, the founder becomes, functionally, an employee. Production targets. Scheduling requirements. Operational oversight from a corporate entity they didn’t choose. Clinical autonomy provisions, if not specifically negotiated, can be narrow to nonexistent.
You didn’t leave the hospital system to recreate it. The deal structure on paper is what determines whether you did.
Note: because these structures involve healthcare business transactions, MSO formation, and clinical autonomy provisions, the corporate practice of medicine doctrine applies — and it varies by state. A healthcare M&A attorney alongside your M&A advisor is essential, not optional.
How Long Does It Take to Sell a Med Spa to Private Equity?
Plan for 9–18 months from the start of a formal process to wire.
Nine months is achievable — if the practice is well-prepared, financials are clean, and a competitive process launches with multiple qualified buyers. Eighteen months is more typical when strategic preparation is needed first: reducing owner concentration, cleaning up financials, addressing SOP documentation, and resolving any compliance exposure before diligence begins.
The founder who spends 12 months preparing before going to market almost always outperforms the founder who rushes from a standing start. The preparation period isn’t lost time. It’s deal value being built.
The timeline that costs the most: “one more year.” Waiting for another year of revenue growth to justify a higher price is the most expensive decision most founders make — and they don’t realize it until after closing.
Buyers don’t pay for trailing revenue peaks. They pay for forward EBITDA potential. Going to market at peak revenue but exhausted, with compressed margins from device financing and no documented systems, produces a worse outcome than going to market 18 months earlier, well-prepared, with a competitive process running. At $1M EBITDA and a 6x market multiple, a compression to 5x costs you $1M in deal value for doing nothing but waiting.
What to Do If You’ve Already Received an Unsolicited Offer
First: Do not respond substantively. The “just a conversation” call is not just a conversation. Everything disclosed before an advisor is in place is used to construct a lower bid. Information, once disclosed, doesn’t un-disclose.
Second: Get a second opinion from someone who knows this market specifically. Not your CPA — they optimize taxes, not deal value. Not a generalist broker — they don’t have relationships with the 30+ active PE platforms and can’t run a competitive process. A specialized M&A advisor who has closed medical aesthetics transactions, knows the active buyer pool, and can tell you in 30 minutes whether the offer you have is a floor or something close to a ceiling.
Third: Understand that you have more leverage than you feel right now. The market is only 3%–4% consolidated. There are 30+ buyers. The offer you received exists specifically to prevent a competitive process from starting — because the buyer knows they cannot win one at the same price.
In one documented case, a founder received unsolicited offers in the 4x–6x range. After a 9-month competitive process run by a qualified M&A advisor, the deal closed at 11.2x. The practice didn’t change. The process did.
What Comes Next
The practice you built over 10–20 years deserves a process as serious as the years you put in. Not a reactive conversation with one buyer. Not a rushed close because you’re exhausted. A structured, competitive, advisor-managed process that forces every qualified buyer to show their real ceiling — and delivers the largest possible wire on closing day.
The wire is the only number that matters. Not the headline LOI. Not the earn-out projection. Not the rollover equity story. The guaranteed cash in your account, after-tax, on day one.
That number is determined almost entirely by what happens before you sign an LOI. Which means the most important decision in this process happens before the process formally begins.
Get a Second Opinion Before You Respond to Any Offer
One 30-minute call with Bill Walker. No obligation. No pitch. Just a straight read on where you stand — what your practice is likely worth in today’s market, whether the offer you have is fair, and what a properly structured process would look like for you.
Bill Walker is the CEO of Aesthetic Brokers, a sell-side M&A advisory firm exclusively serving the aesthetic industry. Based in La Jolla, CA — and operating nationally — Aesthetic Brokers represents founders in transactions ranging from single-location exits to multi-platform deals. If we’re the right fit, you’ll know in the first call. If we’re not, you’ll still walk away with more clarity than you had before.
Schedule Your 30-Minute Call →
⚠️ Disclaimer: This article is for informational purposes only and does not constitute financial, legal, or investment advice. Transaction outcomes vary based on individual practice characteristics, market conditions, and deal structure. EBITDA multiples and deal values cited reflect documented market ranges and specific case outcomes — they are not guarantees or representations of typical results. Consult a qualified M&A advisor before making any transaction decisions. Because this article addresses healthcare business transactions, note that MSO structure, clinical autonomy provisions, and post-sale employment arrangements are subject to state-specific healthcare regulatory compliance requirements, including the corporate practice of medicine doctrine. Engage qualified healthcare M&A legal counsel alongside any M&A advisor.
Frequently Asked Questions
How much is my med spa worth to a private equity firm?
Valuation is driven primarily by adjusted EBITDA, not gross revenue. A $1.5M revenue practice with 20% margins and low owner concentration can outperform a $2.5M revenue practice with 3% margins in a PE transaction. Single-location med spas currently transact at 4x–9x adjusted EBITDA; multi-location platforms reach 7x–13x+. Key variables that move your specific multiple: how much of the clinical work you personally perform, revenue mix (recurring vs. one-time), EBITDA margin, lease terms, and whether you have documented operational systems in place. The only way to know your true market value is through a competitive process — not an unsolicited offer from a single buyer.
What happens if I respond to a PE offer without an advisor?
You begin disclosing information that the buyer uses to price a lower offer — before any structured process exists to create competitive tension. 60%+ of med spa owners engage PE buyers without representation, inadvertently setting the terms of the conversation before an advisor can protect their position. Unrepresented sellers achieve on average 23% lower EBITDA multiples than represented sellers (HealthFMV benchmarking). The “friendly first call” is the most dangerous moment: it is not casual, and nothing said in it is forgotten when the offer is constructed.
What is the difference between a PE affiliation and a DSO deal?
In a PE affiliation, you typically sell the management entity while retaining clinical autonomy. You remain the face of the practice through a negotiated commitment period — typically 2–5 years — with an equity rollover that participates in the platform’s future exit. In a DSO workback structure, the founder transitions into an employment or production-based relationship with the acquiring entity, subject to scheduling requirements, performance metrics, and operational oversight. The commitment period length, clinical autonomy provisions, equity rollover percentage, and non-compete scope are all negotiable before the LOI is signed — and almost impossible to renegotiate after. Most founders don’t know which structure they’re being offered until they’re already inside the conversation.
Listen to the full episode on Spotify: Aesthetics Appeal
What a Financial Analysis Actually Reveals About Your Aesthetic Practice’s Sale Value